We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

53 hedge funds and large institutions have $49M invested in NeuBase Therapeutics, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 20 increasing their positions, 12 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 12

43% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 7

6% more funds holding

Funds holding: 50 → 53 (+3)

4% less capital invested

Capital invested by funds: $51M → $49M (-$1.95M)

Holders
53
Holders Change
+3
Holders Change %
+6%
% of All Funds
0.94%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
20
Reduced
12
Closed
7
Calls
$17K
Puts
–
Net Calls
+$17K
Net Calls Change
+$17K

Top Buyers

Rank Fund Capital Flow
1
PCM
Prelude Capital Management
New York
+$2.52M
2
DC
Davenport & Co
Virginia
+$482K
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$333K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$322K
5
JP Morgan Chase
JP Morgan Chase
New York
+$310K

Top Sellers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
-$1.14M
2
Renaissance Technologies
Renaissance Technologies
New York
-$1.09M
3
MAM
Martingale Asset Management
Massachusetts
-$324K
4
N
Nuveen
North Carolina
-$273K
5
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
-$259K
Name Holding Trade Value Shares
Change 		Change in
Stake
GC
1
Greenlight Capital
New York
$14.2M – – –
BlackRock
2
BlackRock
New York
$6.5M +$186K +1,147 +3%
Vanguard Group
3
Vanguard Group
Pennsylvania
$6.46M +$67.6K +417 +0.9%
Renaissance Technologies
4
Renaissance Technologies
New York
$2.95M -$1.09M -6,718 -24%
PCM
5
Prelude Capital Management
New York
$2.17M +$2.52M +15,550 New
SCM
6
Sio Capital Management
New York
$2.05M -$86.5K -534 -4%
State Street
7
State Street
Massachusetts
$1.78M -$180K -1,112 -8%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$1.77M +$120K +741 +6%
Northern Trust
9
Northern Trust
Illinois
$1.39M +$28.4K +175 +2%
FWM
10
Frontier Wealth Management
Missouri
$1.01M – – –
Bank of New York Mellon
11
Bank of New York Mellon
New York
$870K +$268K +1,652 +36%
GCP
12
GSA Capital Partners
United Kingdom
$849K +$201K +1,240 +26%
N
13
Nuveen
North Carolina
$805K -$273K -1,686 -23%
JAMONY
14
Jacob Asset Management of New York
California
$723K +$839K +5,175 New
Goldman Sachs
15
Goldman Sachs
New York
$625K +$21.6K +133 +3%
DC
16
Davenport & Co
Virginia
$416K +$482K +2,975 New
TAM
17
Tocqueville Asset Management
New York
$364K +$257K +1,585 +156%
First Trust Advisors
18
First Trust Advisors
Illinois
$344K -$18.1K -112 -4%
JP Morgan Chase
19
JP Morgan Chase
New York
$340K +$310K +1,913 +371%
Citadel Advisors
20
Citadel Advisors
Florida
$293K +$122K +755 +56%
Charles Schwab
21
Charles Schwab
California
$288K – – –
D.E. Shaw & Co
22
D.E. Shaw & Co
New York
$288K +$333K +2,058 New
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
$278K +$322K +1,989 New
Wells Fargo
24
Wells Fargo
California
$230K +$21.6K +133 +9%
California State Teachers Retirement System (CalSTRS)
25
California State Teachers Retirement System (CalSTRS)
California
$182K – – –
1
2 3

NBSE Hedge Fund Activity: Q4 2020 in Review

53 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q4 2020, worth a combined $49M — down 3.8% from $51M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new NBSE positions and 7 closed out — a net gain of 3 holders — while 20 added to existing stakes and 12 trimmed.

The largest buyer was Prelude Capital Management, opening a new position worth an estimated $2.52M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $1.14M sold.

  • 53 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q4 2020, up from 50 in Q3 2020.
  • Funds reported $49M of NeuBase Therapeutics, Inc. Common Stock stock for Q4 2020, down 3.8% quarter-over-quarter.
  • 10 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q4 2020 and 7 closed out, a net change of +3 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q4 2020 was Prelude Capital Management, an estimated $2.52M added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q4 2020 was Sphera Funds Management, an estimated $1.14M sold.

Based on aggregated 13F filings for Q4 2020.